Tongji Hospital station

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

Retrieved on: 
Monday, December 11, 2023
Huachung University, Multiple myeloma, Triple, Ophthalmology, HKEX, Safety, SAN, Hope, Treatment, Progression-free survival, ASH, Risk, Tongji Hospital station, Tongji Medical College, Patient, PFS, MRD, Marketing, Trial of the century, Medicine, VCN, Prognosis, Peking Union Medical College, ORR, Cancer, Survival, RRMM, BCMA, Quality of life, Society, Autoimmunity, Pharmaceutical industry, Medical device, Vaccine, Hematology

The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Key Points: 
  • The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.
  • As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients.
  • Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%.
  • Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative.

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Tongji Hospital Begins Installation of Mevion Proton Therapy System

Retrieved on: 
Thursday, August 4, 2022
Research, Hospitals, Health Technology, Other Health, Health, General Health, Other Science, Science, Oncology, Proton, Neoplasm, Varian Medical Systems, Proton therapy, Education, NMPA, PET/CT, PBS, Technology, Central, Tongji Hospital station, National Medical Products Administration, Patient, Multimedia, Huachung University, Tongji Medical College, Scan (company), Hospital, LinkedIn, Research, Science, Cancer, Faculty, Tongji, Risk, Huazhong University of Science and Technology, Partnership, Growth, Medical imaging, Central China

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.
  • This milestone commences the system installation at Tongji Hospitals proton therapy center, the first of its kind in Central China.
  • View the full release here: https://www.businesswire.com/news/home/20220804005161/en/
    Mevion begins system installation at Tongji Hospital in Wuhan, China (Photo: Business Wire)
    The system at Tongji Hospital features Mevions industry leading HYPERSCAN Pencil Beam Scanning (PBS) technology and Adaptive Aperture pMLC.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Tongji hospital selects RayStation

Retrieved on: 
Thursday, April 7, 2022
Proton, RaySearch Laboratories, Karolinska Institute, Tongji Hospital station, Electron, Proton therapy, OIS, Education, Research, HDR, Cancer, Carbon, OAS, Huachung University, Tongji Medical College, Nasdaq Stockholm, Photon, Industry, TPS, Helium, TCS, Ion, Huazhong University of Science and Technology, Technology, Patient, Medical imaging, Weapon

STOCKHOLM, April 7, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Mevion China has placed an order for RayStation* which Mevion China has sold together with Mevion's HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China.

Key Points: 
  • STOCKHOLM, April 7, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Mevion China has placed an order for RayStation* which Mevion China has sold together with Mevion's HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China.
  • RaySearch has about 70 RayStation customers in China through its own subsidiary in the country.
  • Tongji Hospital, Tongji Medical College and Huazhong University of Science & Technology are located in Wuhan in the Hubei Province of China.
  • Tongji Hospital was founded by the German doctor Erich Paulun in Shanghai in 1900.

Mevion Selected to Equip Proton Therapy Center at Tongji Hospital in China

Retrieved on: 
Monday, February 21, 2022
Oncology, Education, Health, Medical Devices, Hospitals, University, Biotechnology, Proton, Risk, Huachung University, Tongji Hospital station, Growth, Scan (company), Education, Adaptation, Varian Medical Systems, Proton therapy, Neoplasm, Huazhong University of Science and Technology, Tongji, Multimedia, Science, Tongji Medical College, Patient, U.S. News & World Report Best Hospitals Rankings, PBS, Faculty, LinkedIn, Research, Medical imaging, Medicine, Central China, Technology, Mevion Medical Systems, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, MEVION MEDICAL SYSTEMS, TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.

Key Points: 
  • Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.
  • Founded in 1900 and listed as the 6th top hospital in Fudans 2020 China Hospital Ranking , Tongji Hospital provides over 6 million annual outpatient visits.
  • The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospitals Optics Valley campus is expected to be completed by December 2022.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in American Society of Gene & Cell Therapy’s Journal, Molecular Therapy

Retrieved on: 
Wednesday, August 18, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dai, RRMM, CAR, Publishing, Program, Efficiency, Research, Huazhong University of Science and Technology, MCL, Epitope, Mutation, Risk, Chronic lymphocytic leukemia, Genetics, Hematopoietic stem cell transplantation, CD5, Medicine, VH, CRISPR, CMC, T-ALL, CLL, Paper, Cell, Huachung University, TCL, Technology, Cell therapy, Hope, Antibody, NMPA, Biotechnology, Degenerative disease, Fragment crystallizable region, Neoplasm, Tongji Hospital station, Molecular Therapy, Gene, Thymocyte, Transplant, Cancer, Society, Antigen, Mantle cell lymphoma, Chemistry, Gene editing, Multimedia, Western literature, Leukemia, HSCT, Patient, Vaccine

View the full release here: https://www.businesswire.com/news/home/20210818005265/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210818005265/en/
    Screenshot of IASO Bios published preclinical results (source: cell.com) (Graphic: Business Wire)
    Molecular Therapy is the official periodical of the American Society of Gene & Cell Therapy, and is published under Cell.
  • In recent years, CAR-T technology has seen numerous breakthroughs and achieved tremendous progress with the development of targets for the treatment B cell malignancies.
  • T cell malignancies include T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoma (TCL)1.
  • CD5 is also expressed in certain B cell malignancies, making CD5 a valid target for the treatment of both T cell and B cell malignancies.